Recruiting Schizophrenia Studies in Kansas City
About Schizophrenia Clinical Trials in Kansas City
Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.
There are currently 1 schizophrenia clinical trials recruiting participants in Kansas City, MO. These studies are seeking a combined 126 participants. Research is being sponsored by ACADIA Pharmaceuticals Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Schizophrenia Clinical Trials in Kansas City — FAQ
Are there schizophrenia clinical trials in Kansas City?
Yes, there are 1 schizophrenia clinical trials currently recruiting in Kansas City, MO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Kansas City?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Kansas City research site will contact you about next steps.
Are clinical trials in Kansas City free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Kansas City studies also compensate for your time and travel.
What schizophrenia treatments are being tested?
The 1 active trials in Kansas City are testing new therapies including novel drugs, biologics, and treatment approaches for schizophrenia.
Data updated September 30, 2026 from ClinicalTrials.gov